Identification of novel polyglutamine-expanded aggregation species in spinal and bulbar muscular atrophy

Brain Res. 2015 Dec 2;1628(Pt B):254-264. doi: 10.1016/j.brainres.2015.09.033. Epub 2015 Oct 8.

Abstract

Polyglutamine-repeat disorders are part of a larger family of neurodegenerative diseases characterized by protein misfolding and aggregation. In spinal and bulbar muscular atrophy (SBMA), polyglutamine expansion within the androgen receptor (AR) causes progressive debilitating muscular atrophy and lower motor neuron loss in males. Although soluble polyglutamine-expanded aggregation species are considered toxic intermediates in the aggregation process, relatively little is known about the spectrum of structures that are formed. Here we identify novel polyglutamine-expanded AR aggregates that are SDS-soluble and bind the toxicity-predicting antibody 3B5H10. Soluble, 3B5H10-reactive aggregation species exist in low-density conformations and are larger by atomic force microscopy, suggesting that they may be less compact than later-stage, insoluble aggregates. We demonstrate disease-relevance in vivo and draw correlations with toxicity in vitro. This article is part of a Special Issue entitled SI: Neuroprotection.

Keywords: Androgen receptor; Polyglutamine; Protein aggregation; Spinal and bulbar muscular atrophy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / metabolism
  • Cerebral Cortex / metabolism
  • Cerebral Cortex / pathology
  • Disease Models, Animal
  • Humans
  • Immunoprecipitation
  • Male
  • Mice
  • Mice, Transgenic
  • Microscopy, Atomic Force
  • Muscular Disorders, Atrophic / genetics*
  • Muscular Disorders, Atrophic / pathology*
  • PC12 Cells
  • Peptides / genetics*
  • Peptides / immunology
  • Peptides / metabolism*
  • Rats
  • Receptors, Androgen / genetics*
  • Spinal Cord / metabolism*
  • Transfection

Substances

  • Antibodies
  • Peptides
  • Receptors, Androgen
  • polyglutamine